Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Pericentromeric satellite repeat expansions through RNA-derived DNA intermediates in cancer.

Bersani F, Lee E, Kharchenko PV, Xu AW, Liu M, Xega K, MacKenzie OC, Brannigan BW, Wittner BS, Jung H, Ramaswamy S, Park PJ, Maheswaran S, Ting DT, Haber DA.

Proc Natl Acad Sci U S A. 2015 Dec 8;112(49):15148-53. doi: 10.1073/pnas.1518008112. Epub 2015 Nov 2.

2.

RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance.

Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, Desai R, Fox DB, Brannigan BW, Trautwein J, Arora KS, Desai N, Dahl DM, Sequist LV, Smith MR, Kapur R, Wu CL, Shioda T, Ramaswamy S, Ting DT, Toner M, Maheswaran S, Haber DA.

Science. 2015 Sep 18;349(6254):1351-6. doi: 10.1126/science.aab0917.

3.

The WTX Tumor Suppressor Interacts with the Transcriptional Corepressor TRIM28.

Kim WJ, Wittner BS, Amzallag A, Brannigan BW, Ting DT, Ramaswamy S, Maheswaran S, Haber DA.

J Biol Chem. 2015 Jun 5;290(23):14381-90. doi: 10.1074/jbc.M114.631945. Epub 2015 Apr 16.

4.

Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells.

Ting DT, Wittner BS, Ligorio M, Vincent Jordan N, Shah AM, Miyamoto DT, Aceto N, Bersani F, Brannigan BW, Xega K, Ciciliano JC, Zhu H, MacKenzie OC, Trautwein J, Arora KS, Shahid M, Ellis HL, Qu N, Bardeesy N, Rivera MN, Deshpande V, Ferrone CR, Kapur R, Ramaswamy S, Shioda T, Toner M, Maheswaran S, Haber DA.

Cell Rep. 2014 Sep 25;8(6):1905-1918. doi: 10.1016/j.celrep.2014.08.029. Epub 2014 Sep 18.

5.

Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis.

Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, Brannigan BW, Kapur R, Stott SL, Shioda T, Ramaswamy S, Ting DT, Lin CP, Toner M, Haber DA, Maheswaran S.

Cell. 2014 Aug 28;158(5):1110-1122. doi: 10.1016/j.cell.2014.07.013.

6.

Isolation and molecular characterization of circulating melanoma cells.

Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, McMahon M, Bosenberg MW, Stott SL, Ting DT, Ramaswamy S, Toner M, Fisher DE, Maheswaran S, Haber DA.

Cell Rep. 2014 May 8;7(3):645-53. doi: 10.1016/j.celrep.2014.03.039. Epub 2014 Apr 18.

7.

Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.

Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu CL, Sequist LV, Smith MR, Ramaswamy S, Toner M, Maheswaran S, Haber DA.

Cancer Discov. 2012 Nov;2(11):995-1003. doi: 10.1158/2159-8290.CD-12-0222. Epub 2012 Oct 23.

8.

RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis.

Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, Ciciliano JC, Smas ME, Winokur D, Gilman AJ, Ulman MJ, Xega K, Contino G, Alagesan B, Brannigan BW, Milos PM, Ryan DP, Sequist LV, Bardeesy N, Ramaswamy S, Toner M, Maheswaran S, Haber DA.

Nature. 2012 Jul 26;487(7408):510-3. doi: 10.1038/nature11217. Erratum in: Nature. 2012 Oct 25;490(7421):570.

9.

Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers.

Ting DT, Lipson D, Paul S, Brannigan BW, Akhavanfard S, Coffman EJ, Contino G, Deshpande V, Iafrate AJ, Letovsky S, Rivera MN, Bardeesy N, Maheswaran S, Haber DA.

Science. 2011 Feb 4;331(6017):593-6. doi: 10.1126/science.1200801. Epub 2011 Jan 13.

10.

Amplification-free digital gene expression profiling from minute cell quantities.

Ozsolak F, Ting DT, Wittner BS, Brannigan BW, Paul S, Bardeesy N, Ramaswamy S, Milos PM, Haber DA.

Nat Methods. 2010 Aug;7(8):619-21. doi: 10.1038/nmeth.1480. Epub 2010 Jul 18.

11.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Greninger P, Nitta M, Sadow PM, Sooriyakumar G, Brannigan BW, Ulman MJ, Perera RM, Wang R, Tam A, Ma XJ, Erlander M, Sgroi DC, Rocco JW, Lingen MW, Cohen EE, Louis DN, Settleman J, Haber DA.

Cancer Res. 2010 Mar 15;70(6):2158-64. doi: 10.1158/0008-5472.CAN-09-3458. Epub 2010 Mar 9.

12.

Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator Claspin.

Zhang J, Song YH, Brannigan BW, Wahrer DC, Schiripo TA, Harris PL, Haserlat SM, Ulkus LE, Shannon KM, Garber JE, Freedman ML, Henderson BE, Zou L, Sgroi DC, Haber DA, Bell DW.

Mol Cancer Res. 2009 Sep;7(9):1510-6. doi: 10.1158/1541-7786.MCR-09-0033. Epub 2009 Sep 8.

13.

Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.

McDermott U, Ames RY, Iafrate AJ, Maheswaran S, Stubbs H, Greninger P, McCutcheon K, Milano R, Tam A, Lee DY, Lucien L, Brannigan BW, Ulkus LE, Ma XJ, Erlander MG, Haber DA, Sharma SV, Settleman J.

Cancer Res. 2009 May 1;69(9):3937-46. doi: 10.1158/0008-5472.CAN-08-4327. Epub 2009 Apr 14.

14.

Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms.

Bell DW, Brannigan BW, Matsuo K, Finkelstein DM, Sordella R, Settleman J, Mitsudomi T, Haber DA.

Clin Cancer Res. 2008 Jul 1;14(13):4079-84. doi: 10.1158/1078-0432.CCR-07-5030.

15.

The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.

Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J, Maheswaran S, Settleman J, Haber DA.

Mol Cancer Ther. 2008 Apr;7(4):874-9. doi: 10.1158/1535-7163.MCT-07-2387.

16.

Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib.

Zampa G, Moscato M, Brannigan BW, Morabito A, Bell DW, Normanno N.

Lung Cancer. 2008 Jun;60(3):452-4. Epub 2008 Feb 20.

PMID:
18079016
17.

An X chromosome gene, WTX, is commonly inactivated in Wilms tumor.

Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim JC, Feinberg AP, Gerald WL, Vargas SO, Chin L, Iafrate AJ, Bell DW, Haber DA.

Science. 2007 Feb 2;315(5812):642-5. Epub 2007 Jan 4.

18.

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.

Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DW.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4283-7.

19.

Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.

Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DW.

Clin Cancer Res. 2005 Nov 15;11(22):8105-8.

20.

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, Haber DA.

Nat Genet. 2005 Dec;37(12):1315-6. Epub 2005 Oct 30.

PMID:
16258541
21.

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA.

J Clin Oncol. 2005 Nov 1;23(31):8081-92. Epub 2005 Oct 3.

PMID:
16204011
22.

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA.

Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70. Epub 2005 May 16.

23.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29.

Supplemental Content

Loading ...
Support Center